Clinical trials: Enoxaparin
Venous Thromboembolism
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Primary objective: To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary…
- Trial name
- NCT00077753
- Testing
- enoxaparin sodium
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 4,726 people
- Sponsor
- Sanofi
Safety Issues, Effect of Drug
Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients
The aim of this study is evaluating safety and effectiveness of Ovine Enoxaparin Sodium in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTEACS) Patients
- Trial name
- NCT06114641
- Testing
- Enoxaparin sodium injection
- Where
- 3 sites in Indonesia
- Volunteers
- 220 people
- Sponsor
- PT Bio Farma
Medical Prevention Therapy
Canadian Outpatient VTE Management Registry
Primary Objective: To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings.
- Trial name
- RECOVERY (NCT01133002)
- Where
- Canada
- Volunteers
- 915 people
- Sponsor
- Sanofi
Physiologic Venous Dilation, Air Travel
Randomized Assessor-Masked Trial of Moderate Graduated Compression Stockings for Popliteal Vein Dilation During Long-Haul Economy-Class Air Travel After Aesthetic Surgery
This randomized assessor-masked trial will evaluate whether knee-high moderate graduated compression stockings reduce popliteal vein dilation during long-haul economy-class air travel to Bogota.
- Trial name
- NCT07810192
- Testing
- Enoxaparine, Knee-High Graduated Compression Stockings, Standardized Bilateral Popliteal Vein Ultrasound
- Where
- Colombia
- Volunteers
- 160 people
- Sponsor
- Research Inc
Venous Thrombosis
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without…
- Trial name
- NCT00440193
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
- Where
- 324 sites in United States, Australia and 32 more
- Volunteers
- 3,449 people
- Sponsor
- Bayer
Healthy
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
- Trial name
- NCT03363477
- Testing
- Enoxaparin, Clexane
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Thromboembolism
Michelangelo - Oasis 5
Study Objectives PRIMARY OBJECTIVE: To evaluate whether fondaparinux is at least as effective as or superior to enoxaparin in preventing death, myocardial infarction or refactory ischemia up to Day 9 in the acute treatment of…
- Trial name
- NCT00139815
- Testing
- Fondaparinux, enoxaparin
- Volunteers
- 20,078 people
- Sponsor
- GlaxoSmithKline
Thromboembolism
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.
- Trial name
- NCT00353678
- Testing
- YM150
- Where
- 79 sites in Austria, Bosnia and Herzegovina and 15 more
- Volunteers
- 1,141 people
- Sponsor
- Astellas Pharma Inc
Venous Thromboembolism
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
In individuals with obesity, the optimal dosing and duration of venous thromboembolism (VTE) prophylaxis in settings representing acute medical illness or surgery is limited due to lack of randomized controlled trials (RCTs)…
- Trial name
- NCT05819125
- Where
- United States
- Volunteers
- 21,000 people
- Sponsor
- Sanofi
Knee Arthroplasty, Total
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
- Trial name
- NCT06180889
- Testing
- Enoxaparin, KN060 Low, KN060 Middle
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Suzhou Alphamab Co., Ltd.
Circulatory Disease
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total…
- Trial name
- NCT06963320
- Testing
- H001 Capsule 200mg-qd, Enoxaparin Sodium Injection, H001 Capsule 300mg-qd
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Prevention, Venous Thromboembolism
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Trial name
- NCT01181167
- Testing
- edoxaban, enoxaparin sodium
- Where
- 2 sites in Japan
- Volunteers
- 610 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Thromboembolism
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
- Trial name
- NCT00375609
- Testing
- Betrixaban, Enoxaparin
- Where
- Canada
- Volunteers
- 215 people
- Sponsor
- Portola Pharmaceuticals
Total Knee Replacement, Total Hip Replacement
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs.
- Trial name
- NCT00074828
- Testing
- LY517717, enoxaparin
- Where
- 8 sites in Australia, Austria and 6 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Deep Vein Thrombosis
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Deep-vein thrombosis (DVT) is a common but under-diagnosed medical condition that occurs when a thrombus forms in one of the large veins, usually in the lower limbs, leading to either partial or complete blocked circulation.
- Trial name
- NCT01880216
- Testing
- Bemiparin sodium, Enoxaparin sodium
- Where
- 25 sites in Georgia, Russia
- Volunteers
- 312 people
- Sponsor
- Berlin-Chemie AG Menarini Group
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare…
- Trial name
- ADVANCE-2 (NCT00452530)
- Testing
- Enoxaparin, Apixaban
- Where
- 122 sites in Austria, Belgium and 25 more
- Volunteers
- 3,221 people
- Sponsor
- Bristol-Myers Squibb
Myocardial Infarction
A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting
The primary objective of ASSENT 3 Plus (the same as for ASSENT 3) was to evaluate the safety and efficacy of full dose tenecteplase combined with unfractionated heparin (UFH, group A) and full dose tenecteplase combined with…
- Trial name
- ASSENT 3 Plus (NCT02181998)
- Testing
- Full dose tenecteplase, Unfractioned heparin, Enoxaparin
- Volunteers
- 1,606 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism, Knee Replacement
ARIXTRA Local Study For Registration In China.
This is a local registration study in China to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components.
- Conditions
- Thromboembolism, Knee Replacement, Hip Replacement
- Trial name
- NCT00328939
- Testing
- ARIXTRA infusion, Enoxaparine infusion
- Where
- 7 sites in China
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim